|
CA1172255A
(fr)
*
|
1980-12-11 |
1984-08-07 |
Robert R. Covington |
Methode de preparation de buspirone
|
|
JPH0635450B2
(ja)
*
|
1984-03-16 |
1994-05-11 |
三井東圧化学株式会社 |
チオシアノピリミジン誘導体、その製造法および農園芸用殺菌剤
|
|
CA2144974C
(fr)
*
|
1992-09-18 |
2000-03-28 |
Nobuyuki Takahashi |
Derive de la camphidine, production et utilisation
|
|
US5658923A
(en)
*
|
1992-09-18 |
1997-08-19 |
Asahi Kasei Kogyo Kabushiki Kaisha |
Azepine derivatives and use thereof
|
|
CA2208900C
(fr)
*
|
1996-07-18 |
2006-08-01 |
Lonza Ag |
Methode de preparation de pyrimidine-2-carboxylates
|
|
EA200000840A1
(ru)
|
1998-02-17 |
2001-02-26 |
Туларик, Инк. |
Антивирусные производные пиримидина
|
|
US6410726B1
(en)
|
2000-01-12 |
2002-06-25 |
Tularik Inc. |
Arylsulfonic acid salts of pyrimidine-based antiviral
|
|
EA013811B1
(ru)
*
|
2002-11-21 |
2010-08-30 |
Новартис Вэксинес Энд Дайэгностикс, Инк. |
2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
|
|
MXPA05007485A
(es)
|
2003-01-14 |
2006-01-30 |
Arena Pharm Inc |
Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
|
|
EP1927594A1
(fr)
*
|
2003-01-14 |
2008-06-04 |
Arena Pharmaceuticals, Inc. |
Dérivés d'aryle et d'hétéroaryle 1,2,3-trisubstitués en tant que modulateurs du métabolisme et la prévention et le traitement de maladies liées à celui-ci, telles que le diabète et l'hyperglycémie
|
|
TW200519094A
(en)
|
2003-07-02 |
2005-06-16 |
Vertex Pharma |
Pyrimidines useful as modulators of voltage-gated ion channels
|
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
|
PL1648874T3
(pl)
|
2003-07-30 |
2012-04-30 |
Xenon Pharmaceuticals Inc |
Pochodne piperazyny i ich zastosowanie jako środków leczniczych
|
|
US7456180B2
(en)
|
2003-07-30 |
2008-11-25 |
Xenon Pharmaceuticals Inc. |
Piperazine derivatives and their use as therapeutic agents
|
|
HUP0400405A3
(en)
*
|
2004-02-10 |
2009-03-30 |
Sanofi Synthelabo |
Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
|
|
JP2007217282A
(ja)
*
|
2004-03-04 |
2007-08-30 |
Astellas Pharma Inc |
置換ピリミジン誘導体
|
|
BRPI0515500A
(pt)
|
2004-09-20 |
2008-07-29 |
Xenon Pharmaceuticals Inc |
derivados piridazina para inibição de estearoil-coa-desaturase
|
|
CN101084211A
(zh)
|
2004-09-20 |
2007-12-05 |
泽农医药公司 |
杂环衍生物及其作为治疗剂的用途
|
|
MX2007003332A
(es)
|
2004-09-20 |
2007-06-05 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
|
|
BRPI0515482A
(pt)
|
2004-09-20 |
2008-07-22 |
Xenon Pharmaceuticals Inc |
derivados heterocìclicos e seus usos como agentes terapêuticos
|
|
AU2005286728A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
|
|
AU2005286647A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
|
MX2007003318A
(es)
|
2004-09-20 |
2007-05-18 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como agentes terapeuticos.
|
|
MY148521A
(en)
|
2005-01-10 |
2013-04-30 |
Arena Pharm Inc |
Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
|
|
DOP2006000010A
(es)
|
2005-01-10 |
2006-07-31 |
Arena Pharm Inc |
Procedimiento para preparar eteres aromáticos
|
|
JP5388574B2
(ja)
|
2005-05-31 |
2014-01-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
イオンチャネルのモジュレーターとして有用なヘテロ環式類
|
|
CA2618646A1
(fr)
|
2005-06-03 |
2007-11-15 |
Xenon Pharmaceuticals Inc. |
Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
|
|
GB0512844D0
(en)
*
|
2005-06-23 |
2005-08-03 |
Novartis Ag |
Organic compounds
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
WO2008098058A1
(fr)
|
2007-02-06 |
2008-08-14 |
Novartis Ag |
Inhibiteurs de la pi3-kinase et procédés de leur utilisation
|
|
BRPI0817211A2
(pt)
|
2007-09-20 |
2017-05-16 |
Irm Llc |
composto composições como moduladores da atividade de gpr119
|
|
CN102046609B
(zh)
|
2008-03-31 |
2014-05-14 |
全药工业株式会社 |
具有细胞保护效果的嘧啶衍生物及其应用
|
|
RS53347B
(sr)
*
|
2008-12-09 |
2014-10-31 |
Gilead Sciences, Inc. |
Modulatori toll-sličnih receptora
|
|
EP3323818A1
(fr)
|
2010-09-22 |
2018-05-23 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles associés
|
|
BR112014007310A2
(pt)
|
2011-09-27 |
2017-04-04 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
|
|
CN103204816B
(zh)
|
2012-01-16 |
2016-04-27 |
中国人民解放军军事医学科学院毒物药物研究所 |
哌嗪基嘧啶类衍生物及其制备方法和用途
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
JP6387360B2
(ja)
|
2013-03-14 |
2018-09-05 |
ノバルティス アーゲー |
変異idhの阻害薬としての3−ピリミジン−4−イル−オキサゾリジン−2−オン
|
|
PL3242666T3
(pl)
|
2015-01-06 |
2025-02-17 |
Arena Pharmaceuticals, Inc. |
Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
|
|
BR112017027656B1
(pt)
|
2015-06-22 |
2023-12-05 |
Arena Pharmaceuticals, Inc. |
Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
|
|
MX2019009841A
(es)
|
2017-02-16 |
2020-01-30 |
Arena Pharm Inc |
Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
|
|
CA3102136A1
(fr)
|
2018-06-06 |
2019-12-12 |
Arena Pharmaceuticals, Inc. |
Methodes de traitement de troubles associes au recepteur s1p1<sb />
|